Request Demo

Last update 23 Jan 2025

Blepharokeratoconjunctivitis

Last update 23 Jan 2025

Basic Info

Synonyms

BKC, 眼睑角膜结膜炎

Introduction-

Drugs associated with Blepharokeratoconjunctivitis

Loteprednol Etabonate

Target

GR x cPLA2α

Mechanism

GR agonists [+1]

Active Org.

Bausch & Lomb, Inc. [+2]

Originator Org.

Bausch & Lomb, Inc.

Active Indication

Dry Eye Syndromes [+12]

Inactive Indication

Blepharitis [+5]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date09 Mar 1998

Recombinant human interleukin-1 receptor antagonist(Tibet Huaxi Pharmaceuticals)

Target

IL1R1

Mechanism

IL1R1 antagonists

Active Org.

Tibet Huaxi Pharmaceuticals Group Co. Ltd.

Originator Org.

Tibet Rhodiola Pharmaceutical Holding Co.

Active Indication

Blepharitis [+2]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

AZR-PED-015

Target-

Mechanism-

Active Org.

Azura Ophthalmics Pty Ltd.Startup

Originator Org.

Azura Ophthalmics Pty Ltd.Startup

Active Indication

Blepharokeratoconjunctivitis

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Blepharokeratoconjunctivitis

ChiCTR2100045073

/ RecruitingNot ApplicableIIT

Application of in vivo confocal microscopy in blepharokeratoconjunctivitis and allergic keratoconjunctivitis

Start Date05 Apr 2021

Sponsor / Collaborator-

CTR20190487

/ RecruitingPhase 2

重组人白细胞介素-1 受体拮抗剂（rhIL-1Ra）滴眼液治疗轻、中度睑缘炎相关角结膜炎（BKC）的安全性和有效性的IIa 期临床试验

[Translation] Phase IIa clinical trial of the safety and efficacy of recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) eye drops in the treatment of mild to moderate blepharitis-associated keratoconjunctivitis (BKC)

评估不同剂量rhIL-1Ra 在轻、中度BKC 受试者中的安全性和有效性

[Translation]

To evaluate the safety and efficacy of different doses of rhIL-1Ra in subjects with mild to moderate BKC

Start Date18 Apr 2019

Sponsor / Collaborator

Tibet Huaxi Pharmaceuticals Group Co. Ltd.

NCT03383276

/ Unknown statusPhase 1IIT

A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

The purpose of this study is to assess the safety and tolerability of ocular administration of Topical Interleukin-1-Receptor Antagonist in healthy volunteers. Additionally, the PK of Interleukin-1-Receptor Antagonist will be assessed.

Start Date18 Dec 2017

Sponsor / Collaborator

Beijing Tongren Hospital

[+1]

100 Clinical Results associated with Blepharokeratoconjunctivitis

100 Translational Medicine associated with Blepharokeratoconjunctivitis

0 Patents (Medical) associated with Blepharokeratoconjunctivitis

Literatures (Medical) associated with Blepharokeratoconjunctivitis

25 Nov 2024·Ocular Immunology and Inflammation

Corneal Manifestations in Patients with Hidradenitis Suppurativa

Review

Author: Huang, Jordan J. ; Li, Wendy J. ; Martinez, Jaime D. ; Chang, Victoria S.

PURPOSETo report two cases of bilateral blepharokeratoconjunctivitis associated with hidradenitis suppurativa (HS).METHODSCase report and literature review. The clinical courses of two patients with HS, including ocular presentation and medical management, are described.RESULTSTwo female patients aged 18 and 23-years-old with severe HS presented with bilateral blepharokeratoconjunctivitis. Shared slit lamp findings included bilateral corneal neovascularization and inferior corneal thinning. Systemic immunosuppression was needed in the first case, which resulted in improvement in the patient's ophthalmic and dermatological findings.CONCLUSIONWe report two cases of bilateral blepharokeratoconjunctivitis in two patients with severe HS. To our knowledge, this association has not previously been described in the literature. Clinicians should be aware of this association given its potentially visually devastating manifestations and the need for early therapeutic interventions.

01 Sep 2024·Journal of Pediatric Ophthalmology & Strabismus

Long-term, Low-Dose Oral Azithromycin Treatment for Chronic Severe Bilateral Blepharokeratoconjunctivitis in Pediatric Patients

Article

Author: Ozmen, Ahmet Tuncer ; Akova, Berna ; Yildiz, Meral ; Baykara, Mehmet ; Hasanova, Shole ; Sari, Esin Sogutlu

Purpose:To evaluate the efficacy and safety of oral azithromycin treatment combined with topical antibiotic and anti-inflammatory agents in pediatric patients with chronic severe bilateral blepharokeratoconjunctivitis.Methods:Patients younger than 14 years with chronic and severe bilateral blepharokeratoconjunctivitis were reviewed retrospectively. Consecutive patients receiving oral azithromycin treatment were included. All patients received oral azithromycin (5 mg/kg/single dose daily) for at least 4 weeks combined with topical antibiotic and anti-inflammatory agents. Before and after the treatment, clinical symptoms were noted, and corneal and conjunctival fluorescein staining and corneal neovascularization were graded. Meibomian gland secretion and meibomian gland plugging were also assessed. All patients completed at least 3 months of follow-up after completion of the oral azithromycin treatment. Patients' clinical data at the time of diagnosis and last follow-up visit were statistically compared.Results: Twenty-nine children (58 eyes, mean age of 6.51 years) were included. The mean time of oral azithromycin use was 5.87 weeks (range: 4 to 10 weeks). Clinical symptoms and signs and visual acuity were significantly improved after treatment. The mean fluorescein staining and corneal neovascularization grades and meibomian gland secretion and meibomian gland plugging scores also improved after treatment ( P < .001). Eyelid distortion or fornix shortening was not observed. At the last follow-up visit, all patients were stable with treatment only with daily eyelid hygiene, topical cyclosporine, and artificial tears. Conclusions:Long-term, low-dose oral azithromycin combined with topical antibiotic and anti-inflammatory agents is an effective treatment option for pediatric patients with chronic severe bilateral blepharokeratoconjunctivitis. [ J Pediatr Ophthalmol Strabismus . 2024;61(5):358–364.]

01 Sep 2024·HIV Medicine

Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat

Article

Author: O'Hara, Geraldine ; Douthwaite, Sam ; Brown, Lottie ; Robbie, Scott ; Islam, Meriam ; Downie, Catriona ; Sargent, Pippa ; Kulasegaram, Ranjababu ; Milligan, Iain D. ; Hassan, Ali ; Aarons, Emma

AbstractBackgroundPeople living with HIV are disproportionately represented among people with severe mpox. Mild and self‐limiting conjunctival involvement has been well‐documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first‐line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox.Case ReportHere, we describe a case of sight‐threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Blepharokeratoconjunctivitis

Basic Info

Related

Analysis